Sign In

Riad Sherif

CEO at Oculis

Riad Sherif is the Chief Executive Officer of Oculis, a clinical-stage biotechnology company focused on developing novel topical treatments for ophthalmic diseases.12 He has been serving in this role since November 2017.1 With over 25 years of experience in the healthcare sector, Dr. Sherif has a strong background in pharmaceuticals, biotech, medtech, and consumer health.1

Career Highlights

  • CEO of Oculis (November 2017 - Present)1
  • Entrepreneur in Residence at Novartis Venture Fund (June 2016 - September 2017)1
  • President of Europe, Middle East & Africa region at Alcon (March 2014 - May 2016)1
  • Canada Country CEO & President at Novartis (May 2011 - April 2014)1
  • President, Latin America Region at Novartis (August 2007 - May 2011)1

Education

  • Medical Doctor degree from Université d'Alger1
  • Master's in Medical Management from ESCP Europe1
  • Executive education in Finance and Strategy from Harvard Business School1

Dr. Sherif is known for his expertise in building high-performance organizations and delivering profitable growth across multiple businesses and geographies.1 He is passionate about bringing innovative solutions to patients with unmet medical needs and creating value for shareholders and stakeholders.1

Highlights

May 31 · linkedin

I am honored to announce the election of Robert W. and Dr. Arshad M. Khanani to our Board of Directors by Oculis shareholders.

Robert W.'s deep and broad commercial experiences launching ophthalmology products in the U.S. and globally will be key as Oculis approaches its first potential launch. We also feel very privileged to strengthen our collaboration with Dr Arshad M. Khanani, world-renowned retina expert, who will continue to chair our retina Scientific Advisory Board while joining our Board of Directors.

For full bios and additional detail on Oculis’ Annual General Meeting, including important information on forward-looking statements, see our press release here: https://bit.ly/3VkeKwz

#eyehealth #ophthalmology #biotech #biopharma #eyedisease #leadership

I am honored to announce the election of Robert W. and Dr. Arshad M. Khanani to our Board of Directo
May 14 · linkedin

I am pleased to announced that enrollment in the Phase 2 ACUITY trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) is now completed. With this important milestone, we are now well positioned to report topline results in Q4 2024 as planned.

AON remains an unmet medical and is often the earliest manifestation of central nervous system inflammatory demyelinating disorders like multiple sclerosis (MS) and neuromyelitis optica (NMO). It affects at least half the patients with MS and is the presenting feature in 15–20% of patients. Vision loss in AON secondary to NMO tends to be more severe with less potential for recovery and greater axonal degeneration, as measured by optical coherence tomography (OCT) (Bennett et al., 2014). Several unique features of the afferent visual pathway make the AON model an ideal system to study disease pathogenesis and evaluate potential neuroprotective and myelin repair strategies.

OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator with the potential to become a neuroprotective therapy for AON and other neuro-ophthalmic diseases where protecting retinal neurons is key to preserving patients’ sight. OCS-05 has been granted orphan drug designation for the treatment of AON in both the United States and Europe, highlighting the importance of this unmet medical need.

I would like to extend my gratitude to all our partners for their commitment towards OCS-05 clinical development program.

For additional details, including important information on forward-looking statements, see our press release here https://bit.ly/3wzw336

#ophthalmology #eyedisease #AcuteOpticNeuritis #neurology #clinicaltrials #biopharma #eyehealth #biotech

I am pleased to announced that enrollment in the Phase 2 ACUITY trial evaluating the safety and tole

Related Questions

What are Riad Sherif's key achievements at Oculis?
How did Riad Sherif's role at Novartis Venture Fund prepare him for his position at Oculis?
What innovative solutions has Riad Sherif introduced at Oculis?
How has Riad Sherif's experience in ophthalmology influenced his leadership at Oculis?
What are the main challenges Riad Sherif has faced as CEO of Oculis?
Riad Sherif
Riad Sherif, photo 1
Riad Sherif, photo 2
Add to my network

Location

Lausanne, Vaud, Switzerland